Is Peptide Compounding Review Altering The Investment Case For Hims Shares (HIMS)?

• Hims & Hers Health has broadened its telehealth footprint with Hers Hair launching in the UK and the Hers platform entering Australia, while also adding an experienced Chief Accounting Officer to support its expanding operations.
• The business has been preparing for potential regulatory easing on peptide compounding by acquiring a peptide facility and starting ingredient testing, which directly links recent policy headlines to its vertically integrated care model.
• We will examine how Hims & Hers Health’s peptide preparation reshapes its investment narrative as expansion and regulation begin to intersect.

Spot 33 healthcare AI stocks that, like Hims & Hers Health, are leaning into telehealth, personalised treatment plans, and regulatory catalysts shaping the next wave of digital care.

Hims & Hers Health Investment Narrative Recap

To own Hims & Hers Health, you need to believe its AI driven telehealth engine can keep converting condition specific programs into long lived subscriber relationships, even as it spends heavily on tech, labs, and talent. The latest Hers Hair launch in the UK and Hers rollout in Australia both support that thesis by widening the addressable pool for recurring care.

The near term swing factor still sits in execution on higher complexity categories like GLP 1 weight loss and peptides, plus regulatory clarity around compounding and payments. The biggest risk remains margin pressure from lower margin products and international mix, especially while the company is loss making and cash needs stay elevated.

The Hers Hair launch in the UK is the clearest operational tie in to the current peptide and telehealth story. A fully online, clinician led program that spans consultation, personalised plans, education, and pharmacy fulfilment shows how a vertically integrated care model might absorb future peptide offerings if rules ease.

For you as an investor, that kind of playbook matters more than any single product headline. It points to how Hims & Hers Health could scale multiple specialties on one infrastructure stack, while still facing real execution tests around profitability, regulatory scrutiny on privacy and billing, and the cost of keeping AI and lab investments productive.

Hims & Hers Health’s current analyst narrative points to revenues of US$4.6b and earnings of US$235.7m by 2029, built on an assumed 21.7% yearly revenue growth rate and a shift from today’s reported loss of US$142.0m to those forecast profits. This implies an earnings swing of about US$377.7m over that period.

Uncover why Hims & Hers Health’s fair value indicates an 11% potential upside to its current price, which could narrow quickly.

Exploring Other Perspectives

Some of the most optimistic analysts frame international rollout as the real catalyst. Before this news, the bullish camp was already modelling revenue of about US$5.9b and earnings near US$390.9m by 2029 for Hims & Hers Health. You can now ask whether the fresh U.K. and Australia moves push those expectations even higher or prompt a reset.

Explore 18 other Hims & Hers Health fair value estimates, including one that suggests potential upside of as much as 510% from the current price.

Decide For Yourself

Don’t just follow the ticker. Dig into the data and build a conviction that’s truly your own.

Looking For More Investment Ideas Beyond Hims & Hers Health?

If the Hims & Hers Health story has sharpened your thinking about digital care and risk, you can use that same lens across the wider market by running a few focused screens on Simply Wall St. Aim for a shortlist that matches your own time horizon and risk comfort, rather than chasing the loudest headline.

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com